Kiora Pharmaceuticals, Inc. (KPRX) Income Statement
KPRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKPRX revenue and net income
KPRX profit margins
KPRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −100.2% | — | — | — |
| Operating income | −309.7% | — | — | — |
| Net income | −401.4% | — | — | — |
| EPS (diluted) | −419.5% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KPRX quarterly EPS vs estimates
Kiora Pharmaceuticals beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 6, 2026.
KPRX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | $0 | $12,059 | $12,059 | $2.7M | $1.7M | $407,518 | $669,259 |
| Cost of revenue | $24,801 | $379,508 | $4.0M | $134,028 | $227,273 | $3.3M | $4,889 | $8.1M | $10.3M | $8.4M |
| Gross profit | −$24,801 | $16.0M | −$4.0M | −$134,028 | −$227,273 | −$3.3M | $2.7M | −$6.4M | −$9.9M | −$7.8M |
| Research & development | $10.8M | $4.9M | $4.0M | $3.4M | $5.4M | $3.6M | $5.4M | $8.1M | $10.3M | $8.4M |
| Sales, general & admin | $5.7M | $5.5M | $4.7M | $8.3M | $5.3M | $4.2M | $4.4M | $4.4M | $4.6M | $5.6M |
| Total operating expenses | $9.4M | $11.5M | $12.6M | $12.3M | $14.2M | $3.6M | $9.8M | $12.5M | $15.0M | $14.0M |
| Operating income | −$9.5M | $4.5M | −$12.6M | −$12.3M | −$14.2M | −$6.9M | −$7.0M | −$10.8M | −$14.6M | −$13.3M |
| Interest income | $894,002 | $1.3M | $176,040 | $56,891 | $1,141 | $23,339 | $108,066 | $120,363 | $564 | — |
| Interest expense | $19,960 | $21,446 | $11,132 | $8,599 | $6,851 | $4,186 | $325 | $1,040 | $1,215 | $275 |
| Income before taxes | −$12.1M | $5.7M | −$12.4M | −$13.7M | −$14.0M | −$6.8M | −$7.0M | −$10.7M | −$14.6M | −$13.3M |
| Income taxes | −$1.3M | $2.1M | $90,319 | −$113,010 | −$192,603 | $12,055 | $95,396 | $86,045 | −$1.3M | $3,684 |
| Net income | −$10.8M | $3.6M | −$12.5M | −$13.6M | −$13.8M | −$6.9M | −$7.1M | −$10.8M | −$13.2M | −$13.3M |
| EBITDA | −$12.1M | $5.7M | −$12.4M | −$13.6M | −$13.9M | −$7.5M | −$6.8M | −$10.7M | −$14.5M | −$13.3M |
| EPS (diluted) | −$2.78 | $0.87 | −$24.59 | −$148.94 | −$364.26 | −$316.43 | −$849.60 | −$1542.00 | −$4410.00 | −$4842.00 |
| Gross margin | — | 100.0% | — | — | −1,884.7% | −27,038.7% | 99.8% | −387.5% | −2,434.9% | −1,158.5% |
| Operating margin | — | 28.2% | — | — | −118,051.0% | −56,960.5% | −260.6% | −656.3% | −3,572.7% | −1,994.3% |
| Net margin | — | 22.5% | — | — | −114,194.3% | −56,901.7% | −264.2% | −654.2% | −3,243.5% | −1,993.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $20,000 | $16.0M | $283,872 | $0 |
| Cost of revenue | — | $41,979 | $10,508 | $38,235 | $31,496 | $19,608 | $34,089 | $14,231 | $17,877 | $16,212 | $7,935 | $42,382 |
| Gross profit | — | −$41,979 | −$10,508 | −$38,235 | −$31,496 | −$19,608 | −$16.0M | −$14,231 | −$886,680 | $16.0M | −$7,935 | −$1.1M |
| Research & development | $2.1M | $2.1M | $1.2M | $1.1M | $904,572 | $565,764 | $1.2M | $1.3M | $906,680 | $1.7M | $1.1M | $1.1M |
| Sales, general & admin | $1.4M | $1.6M | $1.5M | $1.4M | $1.4M | $1.5M | $1.4M | $1.4M | $1.6M | $1.3M | $888,485 | $1.4M |
| Total operating expenses | $2.2M | $2.5M | $7.3M | $794,437 | $2.4M | $2.3M | $2.6M | $3.6M | $2.5M | $2.8M | $2.0M | $5.9M |
| Operating income | −$2.2M | −$2.5M | −$7.3M | −$794,437 | −$2.4M | −$2.3M | −$2.6M | −$3.6M | −$2.5M | $13.2M | −$2.0M | −$5.9M |
| Interest income | $146,232 | $139,338 | $190,310 | $201,822 | $225,237 | $276,633 | $438,860 | $248,840 | $342,102 | $223,047 | $45,525 | $49,912 |
| Interest expense | — | — | $19,960 | — | — | — | $21,446 | — | — | — | $36,999 | — |
| Income before taxes | −$2.1M | −$2.4M | −$7.2M | −$616,323 | −$2.3M | −$2.1M | −$2.2M | −$3.4M | −$2.2M | $13.5M | −$2.2M | −$5.8M |
| Income taxes | — | — | −$649,970 | −$643,129 | −$112,057 | $123,006 | $2.1M | — | $3 | −$2 | $90,319 | $3.4M |
| Net income | −$2.1M | −$2.4M | −$6.5M | $26,806 | −$2.2M | −$2.2M | −$4.2M | −$3.4M | −$2.2M | $13.5M | −$2.3M | −$5.8M |
| EBITDA | −$2.1M | −$2.4M | −$5.3M | −$2.5M | −$2.3M | −$2.1M | −$2.4M | −$2.7M | −$2.4M | $13.2M | −$2.2M | −$2.5M |
| EPS (diluted) | −$0.34 | −$0.58 | −$1.73 | $0.01 | −$0.54 | −$0.52 | −$1.21 | −$0.81 | −$0.53 | $3.42 | −$0.47 | −$8.01 |
| Gross margin | — | — | — | — | — | — | — | — | −4,433.4% | 100.0% | −2.8% | — |
| Operating margin | — | — | — | — | — | — | — | — | −12,724.4% | 82.6% | −701.8% | — |
| Net margin | — | — | — | — | — | — | — | — | −11,108.2% | 84.1% | −799.2% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KPRX's financial statements (latest annual report filed March 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KPRX financial results
Kiora Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $10.8 million. Diluted earnings per share came to −$2.78.
See the KPRX stock overview for the latest quote and news, or the KPRX chart for price history and technical indicators.
KPRX income statement FAQ
Does Kiora Pharmaceuticals have revenue?
Kiora Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Kiora Pharmaceuticals profitable?
No. Kiora Pharmaceuticals reported a net loss of $10.8 million in fiscal 2025.
How much does Kiora Pharmaceuticals spend on research and development?
Kiora Pharmaceuticals spent $10.8 million on research and development in fiscal 2025.
What are Kiora Pharmaceuticals's earnings per share?
Kiora Pharmaceuticals earned $-2.78 per diluted share in fiscal 2025, compared with $0.87 a year earlier.
When will Kiora Pharmaceuticals report its next earnings?
Kiora Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 6, 2026.
When does Kiora Pharmaceuticals's fiscal year end?
Kiora Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 25, 2026.